Marie J P, Zittoun R, Thevenin D
Service d'Hèmatologie de l'Hôtel-Dieu, Paris.
Br J Cancer. 1988 Nov;58(5):570-4. doi: 10.1038/bjc.1988.261.
The evolution of in vitro bone marrow clonogenic leukaemic cells (CFU-L) drug sensitivity was studied in 23 patients with acute myeloid leukaemia treated with anthracycline and cytosine arbinoside (ara-C). In 12 patients tested before and after first induction treatment failure (interval: 6 +/- 4 weeks), the sensitivity remained stable for daunorubicin and showed little variation for ara-C. Among eleven patients tested before treatment and at first relapse (interval: 13 +/- 7 months), in vitro CFU-L sensitivity revealed no correlation between the two measurements, and a trend in decreased sensitivity to daunorubicin and ara-C. These findings suggest that induction failures could be related to factors other than simple selection of a resistant CFU-L subclone.
对23例接受蒽环类药物和阿糖胞苷（ara-C）治疗的急性髓性白血病患者的体外骨髓克隆性白血病细胞（CFU-L）药物敏感性演变进行了研究。在12例首次诱导治疗失败前后进行检测的患者中（间隔时间：6±4周），柔红霉素的敏感性保持稳定，阿糖胞苷的敏感性变化不大。在11例治疗前和首次复发时进行检测的患者中（间隔时间：13±7个月），体外CFU-L敏感性显示两次检测结果之间无相关性，且对柔红霉素和阿糖胞苷的敏感性有下降趋势。这些发现表明，诱导治疗失败可能与除单纯选择耐药CFU-L亚克隆之外的其他因素有关。
